MedDataX Logo

Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms

NCT ID: NCT01973855

Last Updated: 2013-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To meet eligibility criteria, this study and informed consent of the syndrome of fever associated with bleeding of infectious diseases, severe patients to carry out multicenter, practical randomized controlled clinical research, to compare the curative effect of western medicine, combining Chinese and western medicine treatment, and security, and pathogenesis of TCM and syndrome, severe immune related factor and syndrome type of traditional Chinese medicine, Chinese medicine prescriptions mechanism research.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized method: using large sample, central randomized, parallel comparison of Chinese and western medicine and western medicine group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Haemorrhagic Fever Dengue Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TCM and Western Medicine

TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicineļ¼šRibavirin 10-15mg per kg every time

Group Type EXPERIMENTAL

Western Medicine

Intervention Type DRUG

Physical cooling,Hydrocortisone

TCM and Western Medicine

Intervention Type DRUG

Third Infectious diseases soup recipe

Western Medicine

Western Medicineļ¼šRibavirin 10-15mg per kg every time

Group Type PLACEBO_COMPARATOR

TCM and Western Medicine

Intervention Type DRUG

Third Infectious diseases soup recipe

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Western Medicine

Physical cooling,Hydrocortisone

Intervention Type DRUG

TCM and Western Medicine

Third Infectious diseases soup recipe

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ribavirin, Second Infectious diseases soup recipe and Ribavirin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Viral diseases, such as dengue fever, kidney of hemorrhagic fever, such as xinjiang hemorrhagic fever; Or clinical has fever associated with bleeding as the main performance, and confirmed as the new emergent infectious diseases

Exclusion Criteria

* Diagnosed with flu, hand, foot and mouth disease, viral hepatitis (except the carrier), liver cirrhosis after hepatitis, AIDS, rabies, encephalitis, polio, measles, German measles, chickenpox, herpes, infectious mononucleosis, infectious atypical pneumonia
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Guangzhou 8th People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xinghua Tan

Director of Department of infection area

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tan X Hua

Role: STUDY_DIRECTOR

Guangzhou 8th hospitol

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xi 'an eighth people's hospital

XiAn, Shanxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tan X Hua

Role: CONTACT

Phone: 13500039656

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xu R Fang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012ZX10004301-003

Identifier Type: -

Identifier Source: org_study_id